CD3-binding molecules capable of binding to human and non-human CD3
AssigneeMacroGenics, Inc.
InventorsLing Huang, Leslie S. Johnson
Life of this patent
Estimating the term…
Abstract
The present invention relates to CD3-binding molecules capable of binding to human and non-human CD3, and in particular to such molecules that are cross-reactive with CD3 of a non-human mammal (e.g., a cynomolgus monkey). The invention also pertains to uses of such antibodies and antigen-binding fragments in the treatment of cancer, autoimmune and/or inflammatory diseases and other conditions.
Claims31
A CD3-binding molecule comprising an antigen-binding fragment of an antibody, wherein said antigen-binding fragment comprises an antibody CD3-specific VL domain and an antibody CD3-specific VH domain, wherein said CD3-specific VL domain and said CD3-specific VH domain form an antigen-binding domain capable of immunospecifically binding to both an epitope of human CD3 and to an epitope of the CD3 of a non-human mammal, wherein:
- (I) said CD3-specific VL domain comprises the three complementarity determining regions (CDRs) of SEQ ID NO:5;
- and
- (II) said CD3-specific VH domain comprises the three complementarity determining regions (CDRs) of SEQ ID NO:7, modified to comprise one or more amino acid substitutions selected from the group consisting of:
- (i) I51T;
- (ii) S52aN;
- (iii) Y52cA;
- (iv) N54S;
- (v) A56T;
- (vi) Y58E;
- (vii) D61A;
- and
- (viii) D65G;
- wherein said numbering is according to the Kabat numbering scheme.
Dependencies are inferred from the claim text.